The Chicago-based company will report its earnings results before the market open on Friday.
Analysts surveyed by Thomson Reuters are expecting AbbVie to report earnings of $1.12 per share on revenue of $6.38 billion.
During the same period last year, the company reported adjusted earnings of 89 cents per share on revenue of $5.45 billion.
The biopharmaceutical company develops and markets therapies that address a range of diseases, such as chronic autoimmune diseases.
Separately, TheStreet Ratings Team has a "buy" rating with a score of B on the stock.
This is driven by a few notable strengths, which should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks the team covers.
The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, expanding profit margins and growth in earnings per share.
The team believes its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: ABBV